U.S. Markets closed

ArrowHead Research indicates 90% reduction in Hepatitis B antigens

Arrowhead Research will host an analyst event today to discuss ARC-520, its RNAi-based candidate designed to treat chronic hepatitis B virus infection. The company will discuss the program and describe new preclinical data showing that a low dose of ARC-520 induced rapid and deep reductions in viral particles and key viral antigens in a chimpanzee chronically infected with hepatitis B virus. Arrowhead identified a well-tolerated dose of ARC-520 that lead to a 95% reduction in circulating viral DNA, and approximately 90% reductions in hepatitis e-antigen and s-antigen, which are thought to be important in establishing a functional cure.